1. Hudson Jones A. Medicine and the Movies: Lorenzo's Oil at Century's End. Ann Intern Med . 2000;133(7):567-571. PubMed
2. Moser H, Dubey P, Fatemi A. Progress in X-linked adrenoleukodystrophy. Curr Opin Neurol . 2004;17(3):263-269. PubMed
3. Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA . 2005;294(24):3131-3134. PubMed
4. Moser HW. Therapy of X-linked adrenoleukodystrophy. NeuroRx . 2006;3(2):246-253. PubMed
5. Pai GS, Khan M, Barbosa E, et al. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Genet Metab . 2000;69(4):312-322. PubMed
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Raymond GV. A phase III trial of Lorenzo's Oil in adrenomyeloneuropathy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2005-[cited 2010 Jun 7]. Available from: http://clinicaltrials.gov/show/NCT00545597NLMIdentifier:NCT00545597 .
7. Arai Y, Kitamura Y, Hayashi M, Oshida K, Shimizu T, Yamashiro Y. Effect of dietary Lorenzo's oil and docosahexaenoic acid treatment for Zellweger syndrome. Congenit Anom (Kyoto) . 2008;48(4):180-182. PubMed
8. Rizzo WB. Lorenzo's oil—hope and disappointment. N Engl J Med . 1993;329(11):801-802. PubMed
9. Deon M, Wajner M, Sirtori LR, et al. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy. J Neurol Sci . 2006;247(2):157-164. PubMed
10. Deon M, Garcia MP, Sitta A, et al. Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect. Metab Brain Dis . 2008;23(1):43-49. PubMed
11. Making rare diseases a public-health and research priority. Lancet . 2008;371(9629):1972. PubMed
12. Semmler A, Köhler W, Jung HH, Weller M, Linnebank M. Therapy of X-linked adrenoleukodystrophy. Expert Rev Neurother . 2008;8(9):1367-1379. PubMed
13. Moser HW, Raymond GV, Lu SE, et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol . 2005;62(7):1073-1080. PubMed
14. Restuccia D, Di Lazzaro V, Valeriani M, et al. Neurophysiologic follow-up of long-term dietary treatment in adult-onset adrenoleukodystrophy. Neurology . 1999;52(4):810-816. PubMed
15. Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol . 2007;3(3):140-151. PubMed
16. Suzuki Y, Imamura A, Shimozawa N, Kondo N. The clinical course of childhood and adolescent adrenoleukodystrophy before and after Lorenzo's oil. Brain Dev . 2001;23(1):30-33. PubMed
17. Tanaka K, Shimizu T, Ohtsuka Y, Yamashiro Y, Oshida K. Early dietary treatments with Lorenzo's oil and docosahexaenoic acid for neurological development in a case with Zellweger syndrome. Brain Dev . 2007;29(9):586-589. PubMed
18. Chai BC, Etches WS, Stewart MW, Siminoski K. Bleeding in a patient taking Lorenzo's oil: evidence for a vascular defect. Postgrad Med J . 1996;72(844):113-114. PubMed
19. Pour RB, Stöckler-Ipsiroglu S, Hunneman DH, et al. Enhanced lymphocyte proliferation in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides. J Inherit Metab Dis . 2000;23(2):113-119. PubMed